Adam P. Boyd

1.2k total citations · 1 hit paper
12 papers, 683 citations indexed

About

Adam P. Boyd is a scholar working on Pathology and Forensic Medicine, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, Adam P. Boyd has authored 12 papers receiving a total of 683 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Pathology and Forensic Medicine, 4 papers in Pulmonary and Respiratory Medicine and 4 papers in Oncology. Recurrent topics in Adam P. Boyd's work include Lymphoma Diagnosis and Treatment (4 papers), T-cell and Retrovirus Studies (3 papers) and Lung Cancer Research Studies (3 papers). Adam P. Boyd is often cited by papers focused on Lymphoma Diagnosis and Treatment (4 papers), T-cell and Retrovirus Studies (3 papers) and Lung Cancer Research Studies (3 papers). Adam P. Boyd collaborates with scholars based in United States, Canada and United Kingdom. Adam P. Boyd's co-authors include Barbara Pro, Owen A. O’Connor, Kerry J. Savage, Jasmine Zain, Leslie Popplewell, Pier Luigi Zinzani, Mary Jo Lechowicz, Lauren Pinter‐Brown, Andrei R. Shustov and Bertrand Coiffier and has published in prestigious journals such as Journal of Clinical Oncology, Blood and International Journal of Radiation Oncology*Biology*Physics.

In The Last Decade

Adam P. Boyd

12 papers receiving 663 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Pralatrexate in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results From the Pivotal PROPEL Study

2011 439 citations Owen A. O’Connor, Barbara Pro et al. Journal of Clinical Oncology profile →

Peers

Countries citing papers authored by Adam P. Boyd

Since Specialization

Citations

This map shows the geographic impact of Adam P. Boyd's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Adam P. Boyd with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Adam P. Boyd more than expected).

Fields of papers citing papers by Adam P. Boyd

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Adam P. Boyd. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Adam P. Boyd. The network helps show where Adam P. Boyd may publish in the future.

Co-authorship network of co-authors of Adam P. Boyd

This figure shows the co-authorship network connecting the top 25 collaborators of Adam P. Boyd. A scholar is included among the top collaborators of Adam P. Boyd based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Adam P. Boyd. Adam P. Boyd is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

12 of 12 papers shown

#	Work	Indexed citations
1	Molecular results and potential biomarkers identified from MILO/ENGOT-ov11 phase 3 study of binimetinib versus physicians choice of chemotherapy (PCC) in recurrent low-grade serous ovarian cancer (LGSOC). 2021 ·Journal of Clinical Oncology ·Rachel N. Grisham, Ignace Vergote, Susana Banerjee, Esther Drill, Michel Fabbro, Mansoor Raza Mirza, Ignacio Romero, Robert L. Coleman, Amit M. Oza, Felix Hilpert, Kathleen N. Moore, Anneke M. Westermann, Carol Aghajanian, Giovanni Scambia, Adam P. Boyd, Jean Cantey-Kiser, David M. O’Malley, John Farley, Nicoletta Colombo, Bradley J. Monk	6
2	Phase 1b/2 study of binimetinib (BINI) in combination with nivolumab (NIVO) or NIVO plus ipilimumab (IPI) in patients (pts) with previously treated microsatellite-stable (MSS) metastatic colorectal cancer (mCRC) with RAS mutation. 2018 ·Journal of Clinical Oncology ·Johanna C. Bendell, Scott Kopetz, (unknown), (unknown), Viviana Bozón, Adam P. Boyd, Jan H.M. Schellens	5
3	The MILO (MEK inhibitor in low-grade serous ovarian cancer)/ENGOT-ov11 study: A multinational, randomized, open-label phase 3 study of binimetinib (MEK162) versus physician’s choice chemotherapy in patients with recurrent or persistent low-grade serous carcinomas of the ovary, fallopian tube, or primary peritoneum. 2015 ·Journal of Clinical Oncology ·Bradley J. Monk, Rachel N. Grisham, Christian Marth, Susana Banerjee, Felix Hilpert, Robert L. Coleman, Éric Pujade-Lauraine, Sandro Pignata, Mansoor Raza Mirza, Amit M. Oza, Josep M. del Campo, Martin K. Oehler, Adam James, Janna Christy‐Bittel, Emma Barrett, Adam P. Boyd, Ignace Vergote	4
4	The MEK Inhibitor in Low-Grade Serous Ovarian Cancer (MILO)/ENGOT-ov11 study: A multinational, randomized, open-label phase 3 study of binimetinib (MEK162) versus physician’s choice chemotherapy in patients with recurrent or persistent low-grade serous carcinomas of the ovary, fallopian tube, or primary peritoneum. 2014 ·Journal of Clinical Oncology ·Bradley J. Monk, Rachel N. Grisham, Christian Marth, Susana Banerjee, Felix Hilpert, Robert L. Coleman, Éric Pujade-Lauraine, Sandro Pignata, Mansoor Raza Mirza, Amit M. Oza, Josep M. del Campo, Martin K. Oehler, Adam James, Janna Christy‐Bittel, Emma Barrett, Adam P. Boyd, Ignace Vergote	7
5	Estimation of treatment effect under non‐proportional hazards and conditionally independent censoring 2012 ·Statistics in Medicine ·Adam P. Boyd, John M. Kittelson, Daniel L. Gillen	14
6	Pralatrexate in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results From the Pivotal PROPEL Study breakdown → 2011 ·Journal of Clinical Oncology ·Owen A. O’Connor, Barbara Pro, Lauren Pinter‐Brown, Nancy L. Bartlett, Leslie Popplewell, Bertrand Coiffier, Mary Jo Lechowicz, Kerry J. Savage, Andrei R. Shustov, Christian Gisselbrecht, Eric D. Jacobsen, Pier Luigi Zinzani, Richard R. Furman, André Goy, Corinne Haïoun, Michael Crump, Jasmine Zain, Eric D. Hsi, Adam P. Boyd, Steven M. Horwitz	439
7	Stem Cell Transplant (SCT) and Pralatrexate Therapy: Outcome of Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma Who Received SCT Prior to or Following Pralatrexate Therapy. 2009 ·Blood ·Leslie Popplewell, Barbara Pro, Eric D. Jacobsen, Sarah McCue Horwitz, Adam P. Boyd, Molly Bruce Patterson, Steven Fruchtman, Owen A. O’Connor	2
8	Correlation Between Baseline Methylmalonic Acid Status and Mucositis Severity in the PROPEL Study: Implications for Vitamin Prophylaxis. 2009 ·Blood ·Barbara Pro, Bertrand Coiffier, Sarah McCue Horwitz, Adam P. Boyd, Ellen Neylon, Steven Fruchtman, Owen A. O’Connor	4
9	PROPEL: A Multi-Center Phase 2 Open-Label Study of Pralatrexate (PDX) with Vitamin B12 and Folic Acid Supplementation in Patients with Replapsed or Refractory Peripheral T-Cell Lymphoma 2008 ·Blood ·Owen A. O’Connor, Barbara Pro, Lauren Pinter‐Brown, Leslie Popplewell, (unknown), Andrei R. Shustov, Mary Jo Lechowicz, Kerry J. Savage, Bertrand Coiffier, Eric D. Jacobsen, Pier Luigi Zinzani, André Goy, Jasmine Zain, (unknown), Molly Bruce Patterson, Adam P. Boyd, M. Saunders, Pablo J. Cagnoni, Sarah McCue Horwitz	15
10	Whole-brain radiotherapy with or without efaproxiral for the treatment of brain metastases: Determinants of response and its prognostic value for subsequent survival 2006 ·International Journal of Radiation OncologyBiologyPhysics ·Baldassarre Stea, John H. Suh, Adam P. Boyd, Pablo J. Cagnoni, Edward Shaw	24
11	Phase III Study of Efaproxiral As an Adjunct to Whole-Brain Radiation Therapy for Brain Metastases 2005 ·Journal of Clinical Oncology ·John H. Suh, Baldassarre Stea, Abdenour Nabid, John J. Kresl, A. Fortin, (unknown), Neil Senzer, Eric L. Chang, Adam P. Boyd, Pablo J. Cagnoni, Edward Shaw	143
12	Phase II Multicenter Study of Induction Chemotherapy Followed by Concurrent Efaproxiral (RSR13) and Thoracic Radiotherapy for Patients With Locally Advanced Non–Small-Cell Lung Cancer 2005 ·Journal of Clinical Oncology ·Hak Choy, Abdenour Nabid, Baldassarre Stea, Charles Scott, Wilson Roa, (unknown), Joseph Ayoub, Colum J Smith, Luís Souhami, Solomon I. Hamburg, William J. Spanos, Harvey Kreisman, Adam P. Boyd, Pablo J. Cagnoni, Walter J. Curran	20

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact